Skip to main content

Table 4 The Committee’s and the sample ranking of technologies accepted by the 2006/7 Basket Committee (monthly cost threshold = 125 NIS)

From: Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?

Technology

Rank Basket Committee

Diagonal

Rank survey - Total

Rank survey - Physicians

Rank survey - Members of the Basket Committee

Rank efficiencya

Crestor Ezetrol

1

1

12

12

10

9

Atacand Ocsaar Diovan Olmetec

2

2

15

15

15

2

Lantus Levemir

3

3

15

15

15

4

Apidra Humalog Novorapid

4

4

15

15

15

7

Eloxatin

5

5

10

10

10

3

Xeloda

6

6

10

10

10

1

Herceptin

7

7

8

8

9

15

Hepsera

8

8

3

3

3

12

Viread

9

9

7

6

7

14

Prevnar

10

10

18

18

18

18

Mabthera

11

11

1

1

1

11

Keppra

12

12

13

13

14

5

Zyprexa

13

13

14

14

13

17

Exjade

14

14

5

4

4

13

Plavix (cardiac)

15

15

6

6

5

8

Growth hormon

16

16

9

9

8

10

Plavix (stroke)

17

17

1

1

1

6

Velcade

18

18

4

5

5

16

  1. aBy international data on cost per QALY gained